DDRI-18 is an inhibitor of nonhomologous end-joining (NHEJ) DNA repair following double strand DNA breaks induced by ionizing radiation, enhancing the effects of DNA-damaging cancer drugs like etoposide, camptothecin and doxorubicin. References: Jun DW, Jeong YS, Kim HJ, Jeong KC, Kim S, Lee CH. Characterization of DDRI-18 (3,3'-(1H,3'H-5,5'-bibenzo[d]imidazole-2,2'-diyl)dianiline), a novel small molecule inhibitor modulating the DNA damage response. Br J Pharmacol. 2012 Sep;167(1):141-50. doi: 10.1111/j.1476-5381.2012.01977.x. PubMed PMID: 22519567; PubMed Central PMCID: PMC3448919.

纯度：≥98%

CAS：4402-18-0